Search results for "Repurposing drug"

showing 1 items of 1 documents

Myotonic dystrophy type 1 drug development: A pipeline toward the market

2021

Highlights • Myotonic dystrophy, a neuromuscular disease, affects at least around half a million people worldwide. • Close to two dozen preclinical and clinical drug development programs active. • Drugs encompass new chemical entities, repurposing, oligonucleotide, and gene therapy. • Tideglusib, mexiletine, and metformin are close to reaching marketing authorization.

0301 basic medicineDrugmedia_common.quotation_subjectMyotonic dystrophyDiseaseBioinformaticsMarketing authorizationMyotonic dystrophy03 medical and health sciences0302 clinical medicineGene therapyDrug DevelopmentDrug DiscoveryMedicineAnimalsHumansAntisense oligonucleotideRepurposingmedia_commonPharmacologybusiness.industryRepurposing drugmedicine.diseaseClinical trialClinical trialDrug repositioning030104 developmental biologyDrug development030220 oncology & carcinogenesisbusinessPost-Screen (Grey)Drug Discovery Today
researchProduct